In this review, we briefly discuss recently published data on female sexual desire, arousal, orgasm and pain, and on medical/iatrogenic factors associated with female sexual function. The studies reviewed highlight a number of important methodological and etiological issues in the study of female sexual function. Researchers are urged to use standardized methods for defining sexual disorders and for selecting patient samples. Placebo-controlled studies are essential for examining the pharmacological aspects of female sexual dysfunction. Evidence suggests that free testosterone levels may be associated with sexual desire in women. Sildenafil citrate increases genital blood flow but may not impact on subjective reports of arousal. Past research implicated the serotonin 5-hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors in female sexual function, while recent data suggest a role for the 5-hydroxytryptamine 3 receptor. Increasing attention is being paid to medical/health conditions that impact sexual function (e.g. neurological conditions, cancer, hysterectomy, and cardiovascular disease).
Introduction
The aim of this review is to discuss brie¯y recently published data on female sexual function as they relate to past relevant research, and to offer suggestions for future investigations. We begin with a short discussion of issues in the classi®cation and diagnosis of female sexual dysfunction, and then summarize the current research on sexual desire, arousal, orgasm and pain, and on medical and iatrogenic factors relating to female sexual function.
The classification and diagnosis of female sexual dysfunction
Research on female sexuality has rapidly increased over the past few years, and this has brought to light the need for an empirically grounded classi®cation system and for the development of validated measures for assessing female sexual dysfunction. The Diagnostic and Statistical Manual of Mental Disorders (DSM), 4th edition [1] delineates sexual problems into disorders of desire (hypoactive sexual desire, sexual aversion), arousal, orgasm, and pain (dyspareunia and vaginismus). This classi®cation system represents an improvement over earlier DSM editions, in that attention is paid to psychological factors such as interpersonal distress. It remains open to criticism, however, in that it lacks objective criteria and is ambiguous with regard to the degree of impairment necessary to warrant clinical diagnosis. Moreover, it conceptualizes sexual desire, arousal, and orgasm as distinct sexual phases, when in actual clinical practice these dif®culties often coexist. In 1998, an interdisciplinary consensus conference panel of 19 experts in female sexual dysfunction was formed to revisit the existing classi®cation system. The panel's recommendations were published in the Journal of Urology 2000 [2
. . ] and were reprinted, together with invited expert comments, in a special edition of the Journal of Sex and Marital Therapy 2001 [3
. . ]. Although modi®cations were made to the DSM-IV system, we agree with the position of Bancroft et al. [4] that, from a clinical perspective, the current system still lacks both therapeutic and prognostic signi®cance, and from a research perspective, it is atheoretical with regard to the determinants of female sexual function.
Despite the dif®culties inherent in the DSM-IV classi®cation system, it remains the most widely utilized and recognized system, and offers some standardization for subject classi®cation. ]. This newly validated 19-item self-report measure of female sexual function provides scores on six domains derived using factor analyses: desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI was developed and normed on 128 women who met DSM-IV criteria for FSAD (age range 21±69 years) and a sample of age-matched controls.
Sexual desire
The high prevalence of HSDD combined with the fact that there are currently no empirically validated treatments for HSDD in women [7] point to the strong need for research in this area of female sexuality. Increasing evidence points to the involvement of androgens in the female sexual drive, although past studies of this nature paint an unclear picture. Many women with hypoactive sexual desire have normal testosterone levels, some women with low testosterone levels have normal sexual drive, and high testosterone levels are not always associated with high libido [8
. . ]. Whereas exogenous testosterone treatment has proved effective for treating a subset of women with low sex drive, most of this research to date has focused on surgically menopausal women [9
. . ]. Most commonly, studies have included women who have undergone oophorectomy with or without hysterectomy, but Rako [10] brought to our attention how hysterectomy may lead to testosterone de®ciency, even when the ovaries are spared as a result of the interruption of blood supply from the uterine artery.
Shiffrin et al. [11 . . ] conducted perhaps the most vigorous study to date of replacement testosterone on sexual responses in 75 women who had undergone oophorectomy and hysterectomy. Using a double-blind, randomized, placebo-controlled, crossover design, the authors examined the effects of 150 and 300 mg of testosterone per day combined with oral estrogen on measures of sexual and overall well-being. Serum free testosterone levels were substantially increased at both treatment levels. Compared with a robust placebo response, measures of sexual desire, orgasm pleasure, and general well-being signi®cantly increased with 300 but not 150 mg testosterone.
Methodological issues pertaining to how testosterone is measured and how the subject population is de®ned may help to explain some of the discrepancies noted in the past literature on testosterone and female sexual desire. presents only inferential evidence based on observational studies and deductive reasoning, he points to the possibility of testosterone receptors in the brain that are linked to the sex drive. Human research to date has focused on the peripheral in¯uence of testosterone on sexual drive; the role of testosterone-mediated central events deserves scienti®c investigation.
Sexual arousal
The enormous success of using sildena®l citrate (Viagra) for treating male erectile disorder has brought increasing attention to the possibility that drugs that affect nitric oxide systems might also be effective in treating FSAD. Partly as a result of this pharmacological enquiry, in the past few years our knowledge of the mechanisms involved in female sexual arousal has increased substantially. Brie¯y, nitric oxide and phosphodiesterase type V (the enzyme responsible for cyclic 3',5'-guanosine monophosphate degradation and nitric oxide production) have been identi®ed in human clitoral and cavernosal smooth muscle [14 . . ]. Published in the past year was an organ bath study [15 . ] showing that sildena®l, a potent phosphodiesterase type V inhibitor, caused a dosedependent relaxation of female rabbit clitoral corpus cavernosum. These ®ndings suggest that sildena®l plays a similar role in facilitating blood¯ow to the clitoral and penile corpus cavernosum and, from this perspective, may be useful for treating FSAD.
To our knowledge, no published controlled studies have examined the effects of sildena®l on sexual arousal in human females. At the 2000 meeting of the International Academy of Sex Research, Laan et al. [16] reported the preliminary results from a double-blind, placebo-controlled, two-way crossover study of 50 mg sildena®l on vaginal and subjective sexual responses in 12 sexually functional women. Sildena®l signi®cantly increased vaginal pulse amplitude responses, but had no impact on subjective perceptions of sexual arousal. Meston [17 . ] discussed the issue of desynchrony between genital and self-reported measures of female sexual arousal commonly noted in laboratory studies of this nature. Whether this sex-speci®c desynchrony is caused by an inability to detect subtle changes in genital blood¯ow, a confound of contrived laboratory settings, or the fact that women may attend more to contextual than physiological cues when estimating their degree of sexual arousal, this perplexing issue has signi®cant implications for developing effective treatments for FSAD. Many of the drugs currently under investigation act as vasodilators with the end goal of increasing blood¯ow into the genitals. Even if the drugs are successful in doing so, the question is whether this will necessarily improve a woman's sexual experience. There is a great need for studies that examine the cause of this desynchrony and that aim at a better understanding of the myriad key factors that contribute to a woman's psychological experience of feeling sexually aroused.
A number of recent case reports and small open studies have reported on the success of using sildena®l for reversing antidepressant-induced sexual side-effects in women. In the past year, Salerian et al.
[18] reported signi®cant improvements in psychotropic-induced sexual dysfunction among 31 women treated with sildena®l. Whereas the sample size used was considerably larger than previous reports of this nature, the lack of a placebo control severely limits the interpretation of these ®ndings. Michelson et al. [19 . . ] examined the comparative effects of 8 weeks' treatment with buspirone, amantadine, or placebo on¯uoxetine-induced sexual dysfunction in women. The authors reported that neither busprione nor amantadine was more effective than placebo in restoring sexual function. That study [19 . . ] was the ®rst placebo-controlled examination of an antidote for antidepressant-induced sexual dysfunction. The null results reported stand in sharp contrast with ®ndings from non-placebo-controlled drug studies published between 1986 and 1998, of which 20 out of 21 reported success in alleviating antidepressant-induced sexual dysfunction [20] 
Medical and iatrogenic factors influencing sexual function
Numerous medical problems are associated with sexual dysfunction, but it is often dif®cult to differentiate between predisposing, precipitating, and maintaining factors. The sexual problem may arise as a result of disease, surgery, medication, or psychological factors, and depending upon the age of the patient, may be confounded with normal age-related declines in sexual functioning [29 . ]. It is important that studies examining the relationship between medical conditions and sexual functioning consider all these potential factors and employ study designs that will help tease them apart. . Retrospective studies may lack accurate recall, and prospective studies must consider the possibility that the pre-surgery levels of sexual function may be arti®cially lowered as a result of, for example, pre-surgery anticipatory anxiety or depression. Several authors have suggested that a validated measure of surgery-related sexual functioning is needed [31, 32] , and that it must be brief enough not to limit subject participation [34] . Confounding factors, such as anxiety, depression, and relationship functioning should also be assessed, as it is feasible that pre-surgical conditions will be most predictive of post-surgical sexual functioning. Green et al. [31] found that pre-surgery depression levels predicted post-surgical sexual adjustment. Diemont et al.
[34] examined sexual functioning in patients receiving dialysis versus those with a renal transplant, and found that sexual dysfunction rates were lower among those with a transplant. Had the study included prospective measures of sexual functioning and potential confounding factors, it may have been possible to identify those factors most predictive of positive and negative outcomes.
A distinction should also be made between the types of surgery, and the degree to which they may physically alter the internal or external genitalia. Sexual functioning may be impaired as a direct result of physical damage to important tissues, as has been hypothesized with hysterectomy ]. Those interested in learning more about drug treatments for female sexual dysfunction are encouraged to read Everaerd and Laan [41] .
During pregnancy and the postpartum period, all women experience profound physical changes (e.g.¯uctuating hormones) that are likely to affect sexual functioning, but other factors that existed before pregnancy (e.g. depression, anxiety, sexual dysfunction, relationship stress, co-morbid medical conditions) may exacerbate these changes. Bitzer and Alder [42 . ] noted that sexual desire and the frequency of intercourse steadily declines throughout pregnancy, and that sexual problems after pregnancy are the norm, rather than the exception. Many of the articles reviewed, however, were published over 10 years ago. Two articles published this year, one examining sexuality during pregnancy [43] , and one examining sexuality during the postpartum period [44] , noted similar results. Also worth noting was the ®nding that only 29% of women discussed sexual issues with their physician, and of those who did not, 76% indicated that they would have liked to (for review of pregnancyrelated sexual dysfunction, see Bitzer and Alder [42 . ]).
As the population continues to age, increasing numbers of women will transition through the menopause. The challenge in menopause research is to differentiate menopausal symptoms and postmenopausal changes from normal aging-related changes and medical problems, as well as lifestyle and psychosocial factors. Ideally, menopausal research should be conducted using prospective, population-based longitudinal studies that follow women from premenopause through to the postmenopause period, as exempli®ed by Dennerstein et al. [45 . . ]. Although these types of studies are costly and time consuming, they are useful in differentiating between non-menopausal and menopausal factors. In addition, as increasing varieties of hormone replacement therapy (HRT) become available, large population-based clinical trials are needed to examine which regimen is most effective and safe for use with various pre-existing conditions, such as breast cancer and cardiovascular disease [46 . ]. Care should be taken before generalizing ®ndings from one country to another, given the wide variation across countries in health risk factors (e.g. smoking and obesity), health surveillance (e.g. screening for breast and cervical cancer), HRT use, as well as nonspeci®c cultural factors such as attitudes about menopause [46 . ]. Ideas and knowledge about menopause may have a profound impact on how it is experienced; for example, Dennerstein et al. [45 . . ] noted that a common menopausal complaint among Australian women, vaginal dryness, was less severe among women with advanced education.
Antidepressant medications
Several reviews have documented a high prevalence of sexual side-effects secondary to almost all the antidepressant drugs currently being prescribed [47, 48] . In a randomized, double-blind, 14-center study of 248 depressed patients, Segraves et al. [49] found buproprion (enhances dopaminergic or noradrenergic function) use was associated with signi®cantly lower rates sexual dysfunction than sertraline (a selective serotonin reuptake inhibitor; SSRI) use. Kennedy et al. [50] found that moclobemide, a reversible monoamine oxidase inhibitor, produced fewer sexual side-effects than venlafaxine, sertraline and paroxetine.
It is not known why SSRI produce sexual side-effects, but some evidence suggests that activation of the 5-hydroxytryptamine (5-HT) 2 receptor impairs sexual functioning, and stimulation of the 5-HT 1A receptor facilitates sexual functioning [8
. . ]. Cyproheptadine acts as a histamine and serotonin (5-HT 2 ) antagonist, and has been reported to reduce antidepressant-induced sexual side-effects. Nefazodone, a 5-HT 2 antagonist that causes an upregulation of 5-HT 1A receptors, reportedly causes fewer sexual side-effects compared with traditional SSRI. Some evidence suggests that the 5-HT 1A agonist, buspirone, may be useful in reversing SSRI-induced sexual dysfunction, although ®ndings from the study by Michelson et al. [19 . . ] noted earlier showed that it was no more effective than placebo. Gelenberg et al. [51] reported positive effects of mirtazapine, a new antidepressant that acts as an antagonist at the alpha2 adrenergic, 5-HT 2 and 5-HT 3 receptors, for reversing SSRI-induced sexual dysfunction, and Berk et al. [52 . ] found that granisetron, a 5-HT 3 antagonist, but not sumatriptan, a 5-HT D agonist, signi®cantly improved antidepressant-induced sexual dysfunction. The ®ndings from these recent studies implicated the 5-HT 3 receptor in female sexual responding, but placebo-controlled studies are essential before con®dent assumptions can be made. Frohlich and Meston [53 . ] reviewed literature that suggested that some sexual side-effects of SSRI may result from the actions of serotonin in the periphery of the body rather than the central nervous system. Approximately 95% of serotonin receptors are located in the periphery of the body, and peripheral serotonin acts on the smooth muscles of the vascular system to produce vasodilation and vasoconstriction, acts on the smooth muscles in the genitals, and is active in peripheral nerve functions, including those of the sexual organs.
With regard to improving patient care, two articles published in the past year deserve mention. Phillips and Slaughter [54] offered physicians suggestions and guidelines to help minimize adverse treatment effects associated with depression, and Kornstein and McEnany [55] discussed issues speci®c to the assessment and treatment of female patients experiencing depression (e.g. menstrual cycle, pregnancy, menopause).
Conclusion
The studies reviewed highlight a number of important methodological and etiological issues in the study of female sexual dysfunction. Researchers are urged to use standardized methods for de®ning sexual disorders, measuring treatment effects, and for selecting patient samples. . ], nonspeci®c factors can dramatically impact treatment outcome effects, and it is essential that pharmacological studies on female sexual dysfunction include a placebo control group. Except to formulate new testable hypotheses, non placebo-controlled studies are misleading and of questionable utility. Studies on medical problems associated with sexual dysfunction must consider the independent contributing factors of disease, surgery, medication, and psychology.
Increasing evidence points to the role of androgens in HSDD, and the studies reviewed indicated that measuring free testosterone levels may be integral to a better understanding of this relationship. Studies suggest that sildena®l may be effective in facilitating blood¯ow to the clitoral corpus cavernosum, but it is unclear whether this will improve a woman's subjective sexual experience. The link between psychological and physiological aspects of female sexual arousal remain poorly understood. Adding to the past literature that implicates the 5-HT 2 and 5-HT 1A serotonin receptors, there is now reason to speculate that the 5-HT 3 receptor may be involved in female sexual function. When exploring sexual disorders we often focus on peripheral mechanisms at the exclusion of central events, and vice versa. Consideration must be given to the potential role of both peripherally and centrally mediated events and to the complex interplay between the two. 
